American Century Companies Inc. Purchases 32,935 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

American Century Companies Inc. boosted its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 16.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 232,356 shares of the company’s stock after acquiring an additional 32,935 shares during the period. American Century Companies Inc. owned 0.11% of Allogene Therapeutics worth $495,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of ALLO. Geode Capital Management LLC raised its holdings in shares of Allogene Therapeutics by 14.4% during the third quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock valued at $9,037,000 after acquiring an additional 407,070 shares in the last quarter. abrdn plc purchased a new position in Allogene Therapeutics during the 4th quarter valued at $776,000. Vontobel Holding Ltd. raised its holdings in Allogene Therapeutics by 788.4% in the 4th quarter. Vontobel Holding Ltd. now owns 195,457 shares of the company’s stock worth $416,000 after purchasing an additional 173,457 shares in the last quarter. Barclays PLC lifted its position in shares of Allogene Therapeutics by 101.5% in the 3rd quarter. Barclays PLC now owns 342,973 shares of the company’s stock worth $959,000 after purchasing an additional 172,745 shares during the period. Finally, BNP Paribas Financial Markets boosted its stake in shares of Allogene Therapeutics by 541.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 46,374 shares of the company’s stock valued at $130,000 after purchasing an additional 39,145 shares in the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Trading Up 5.8 %

Shares of NASDAQ:ALLO opened at $1.45 on Friday. The stock has a fifty day simple moving average of $1.75 and a two-hundred day simple moving average of $2.14. Allogene Therapeutics, Inc. has a 12-month low of $1.23 and a 12-month high of $4.01. The stock has a market capitalization of $315.03 million, a price-to-earnings ratio of -0.93 and a beta of 0.99.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.06. As a group, equities research analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Insiders Place Their Bets

In other news, insider Timothy L. Moore sold 14,746 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total transaction of $25,215.66. Following the transaction, the insider now directly owns 250,713 shares of the company’s stock, valued at $428,719.23. This represents a 5.55 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Zachary Roberts sold 27,199 shares of Allogene Therapeutics stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the sale, the executive vice president now owns 488,054 shares of the company’s stock, valued at $868,736.12. The trade was a 5.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 104,866 shares of company stock valued at $194,461. Insiders own 24.30% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on ALLO. HC Wainwright decreased their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research report on Friday, March 14th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of Allogene Therapeutics in a research report on Friday, March 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $9.29.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).